ADX-038 for Chinese adults with complement-related kidney diseases such as IgA nephropathy
Tests ADX-038, alone and with telitacicept, in Chinese adults with complement-related kidney disease.
Plain-language title generated from the registry record
Registry title: Chinese Adults With Kidney Disease
Key facts
- Where
- Baotou, Beijing, Guiyang, Shandong, Shanghai, Shenzhen, Wuxi, Yantai, and Zhengzhou, ChinaSee the 9 sites
- Phase
- Phase 2
Where in China
- BaotouBaotou, ChinaTaking people
- BeijingBeijing, ChinaTaking people
- GuiyangGuiyang, ChinaTaking people
- ShandongShandong, ChinaTaking people
- ShanghaiShanghai, ChinaTaking people
- ShenzhenShenzhen, ChinaTaking people
- WuxiWuxi, ChinaTaking people
- YantaiYantai, ChinaTaking people
- ZhengzhouZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ADARx Pharmaceuticals, Inc.
- Trial code
- NCT07522099
- Record updated
- 3 September 2026
- Original description
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).Read full original descriptionShow less
A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Inclusion: Mean eGFR greater than or equal to 30 mL/min/1.73m2; Clinical evidence of active kidney disease; Treated with supportive care including an ACE inhibitor or ARB if applicable; Willing to receive required vaccinations; Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy.
Exclusion: Previous kidney transplant or major solid organ transplant; Required renal replacement therapy for more than 72 hours; Current or previous use of C5 or CFB inhibitors (such as eculizumab, ravulizumab or iptacopan); History of recurrent invasive infection; Active TB, HIV or other systemic infection; Rapidly progressive glomerular nephritis or acute kidney injury; Abnormal liver function.